Ignite Creation Date:
2025-12-24 @ 3:36 PM
Ignite Modification Date:
2026-02-25 @ 8:25 PM
Study NCT ID:
NCT02864992
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-12-23
First Post:
2016-07-29
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)
Sponsor:
EMD Serono Research & Development Institute, Inc.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2016-09-13
Start Date Type:
ACTUAL
Primary Completion Date:
2022-05-16
Primary Completion Date Type:
ACTUAL
Completion Date:
2026-04-30
Completion Date Type:
ESTIMATED
First Submit Date:
2016-07-29
First Submit QC Date:
None
Study First Post Date:
2016-08-12
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2023-05-15
Results First Submit QC Date:
None
Results First Post Date:
2023-06-09
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-12-04
Last Update Post Date:
2025-12-23
Last Update Post Date Type:
ESTIMATED